Drug intelligence / Profile preview

mAb6

Development stage: Preclinical
Lead developer: Stainwei Biotech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

mAb6 is a preclinical monoclonal antibody being developed by Stainwei Biotechnology for the treatment of tumors. It is designed to target VEGTA (likely a designation for Vascular Endothelial Growth Factor A), a signaling protein that promotes the growth of new blood vessels. By targeting this pathway, mAb6 aims to exert an anti-angiogenic effect, inhibiting the blood supply required for tumor growth and progression. The drug is currently in the early stages of development within Stainwei's oncology pipeline.

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on mAb6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mAb6.

Explore the full profile